文献速递肺结节与肺癌

派安普利单抗联合化疗一线治疗转移性鳞状非小细胞肺癌:AK105-302随机双盲三期试验

First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
PubMed 文献 · Lancet Respir Med · 2024-01-31

AK105-302是一项多中心随机双盲安慰剂对照三期试验,纳入350例中国晚期鳞状非小细胞肺癌患者,比较派安普利单抗联合紫杉醇卡铂与安慰剂联合化疗。安全性可耐受。

要点

  • 派安普利单抗联合紫杉醇卡铂一线治疗显著改善晚期鳞状NSCLC的PFS。

核心结论

  • 派安普利单抗联合化疗较单纯化疗显著改善晚期鳞状非小细胞肺癌患者的无进展生存期,且安全可耐受。
  • 派安普利单抗联合紫杉醇和卡铂可作为该晚期疾病一线治疗的新选择。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照三期临床试验,在中国74家医院入组患者。
  • 入组标准为18-75岁、组织学或细胞学确诊的局部晚期(IIIb或IIIc期)或转移性(IV期)鳞状非小细胞肺癌,不适合根治性手术及同步或序贯放化疗,ECOG体能状态0-1,未接受过针对局部晚期或转移性NSCLC的全身化疗,至少有一个可测量病灶(RECIST 1.1)。
  • 共筛查485例,随机分配350例(派安普利单抗组175例,安慰剂组175例);324例(93%)为男性,26例(7%)为女性;347例(99%)为汉族。
  • 随机按1:1分配,分层因素为PD-L1肿瘤比例评分(<1% vs 1-49% vs ≥50%)和性别;给药方案为派安普利单抗200 mg或安慰剂联合紫杉醇175 mg/m2和卡铂AUC 5,每3周第1天静脉给药,共4周期,随后派安普利单抗或安慰剂维持治疗。
  • 主要终点为盲态独立影像评审委员会评估的无进展生存期,在意向治疗人群和PD-L1肿瘤比例评分≥1%的患者(PD-L1阳性亚组)中分析;安全性分析纳入所有至少接受一剂研究药物的参与者。

主要发现

  • 派安普利单抗组173例中120例(69%)发生3级或以上治疗中出现的不良事件,安慰剂组175例中119例(68%)发生。

关键数值与推荐

  • 3级或以上治疗中出现的不良事件发生率:派安普利单抗组69%(120/173),安慰剂组68%(119/175)。

临床怎么用

  • 对于既往未接受全身化疗的晚期鳞状非小细胞肺癌患者,可考虑派安普利单抗联合紫杉醇和卡铂作为一线治疗选择。
  • 治疗前应评估PD-L1肿瘤比例评分,PD-L1阳性亚组同样显示显著PFS获益。
  • 治疗期间需监测不良事件,3级或以上不良事件发生率与安慰剂联合化疗组相近。

局限性

  • 研究仅在中国74家医院进行,入组患者以男性(93%)和汉族(99%)为主,结果外推需谨慎。
  • 本次报告的主要终点为无进展生存期,总生存期数据未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Penpulimab is a novel programmed death (PD)-1 inhibitor. This study aimed to establish the efficacy and safety of first line penpulimab plus chemotherapy for advanced squamous non-small-cell lung cancer. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 3 clinical trial enrolled patients with locally advanced or metastatic squamous non-small-cell lung cancer from 74 hospitals in China. Eligible participants were aged 18-75 years, had histologically or cytologically confirmed locally advanced (stage IIIb or IIIc) or metastatic (stage IV) squamous non-small-cell lung cancer, were ineligible to complete surgical resection and concurrent or sequential chemoradiotherapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, did not have previous systemic chemotherapy for locally advanced or metastatic non-small-cell lung cancer, and had one or more measurable lesions according to RECIST (version 1.1). Participants were randomly assigned (1:1) to receive intravenous penpulimab 200 mg or placebo (excipient of penpulimab injection), plus paclitaxel 175 mg/m2 and carboplatin AUC of 5 intravenously on day 1 every 3 weeks for four cycles, followed by penpulimab or placebo as maintenance therapy. Stratification was done according to the PD-L1 tumour proportion score (<1% vs 1-49% vs ≥50%) and sex (male vs female). The participants, investigators, and other research staff were masked to group assignment. The primary outcome was progression-free survival assessed by the masked Independent Radiology Review Committee in the intention-to-treat population and patients with a PD-L1 tumour proportion score of 1% or more (PD-L1-positive subgroup). The primary analysis was based on the intention-to-treat analysis set (ie, all randomly assigned participants) and the PD-L1-positive subgroup. The safety analysis included all participants who received at least one dose of study drug after enrolment. This trial was registered with ClinicalTrials.gov (NCT03866993). FINDINGS: Between Dec 20, 2018, and Oct 10, 2020, 485 patients were screened, and 350 participants were randomly assigned (175 in the penpulimab group and 175 in the placebo group). Of 350 participants, 324 (93%) were male and 26 (7%) were female, and 347 (99%) were of Han ethnicity. In the final analysis (June 1, 2022; median follow-up, 24·7 months [IQR 0-41·4]), the penpulimab group showed an improved progression-free survival compared with the placebo group, both in the intention-to-treat population (median 7·6 months, 95% CI 6·8--9·6 vs 4·2 months, 95% CI 4·2-4·3; HR 0·43, 95% CI 0·33-0·56; p<0·0001) and in the PD-L1-positive subgroup (8·1 months, 5·7-9·7 vs 4·2 months, 4·1-4·3; HR 0·37, 0·27-0·52, p<0·0001). Grade 3 or worse treatment-emergent adverse events occurred in 120 (69%) 173 patients in the penpulimab group and 119 (68%) of 175 in the placebo group. INTERPRETATION: Penpulimab plus chemotherapy significantly improved progression-free survival in patients with advanced squamous non-small-cell lung cancer compared with chemotherapy alone. The treatment was safe and tolerable. Penpulimab combined with paclitaxel and carboplatin is a new option for first-line treatment in patients with this advanced disease. FUNDING: The National Natural Science Foundation of China, Shanghai Municipal Health Commission, Chia Tai Tianqing Pharmaceutical, Akeso.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Zhong H, Sun S, Chen J, et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 2024. PMID: 38309287. doi:10.1016/S2213-2600(23)00431-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。